166196-54-9 Usage
General Description
4-(4-Bromo-1H-pyrazol-3-yl)pyridine is a chemical compound with the molecular formula C9H6BrN3. It is a heterocyclic compound that consists of a pyridine ring attached to a pyrazol ring with a bromine substituent. 4-(4-Bromo-1H-pyrazol-3-yl)pyridine is often used as a building block or intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in medicinal chemistry and drug discovery due to its unique structure and reactivity. 4-(4-Bromo-1H-pyrazol-3-yl)pyridine has various chemical and physical properties that make it a valuable and versatile compound for research and industrial purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 166196-54-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,1,9 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 166196-54:
(8*1)+(7*6)+(6*6)+(5*1)+(4*9)+(3*6)+(2*5)+(1*4)=159
159 % 10 = 9
So 166196-54-9 is a valid CAS Registry Number.
166196-54-9Relevant articles and documents
Potent and selective pyrazole-based inhibitors of B-Raf kinase
Hansen, Joshua D.,Grina, Jonas,Newhouse, Brad,Welch, Mike,Topalov, George,Littman, Nicole,Callejo, Michele,Gloor, Susan,Martinson, Matthew,Laird, Ellen,Brandhuber, Barbara J.,Vigers, Guy,Morales, Tony,Woessner, Rich,Randolph, Nikole,Lyssikatos, Joseph,Olivero, Alan
, p. 4692 - 4695 (2008)
Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated the ability to inhibit downstream ERK phosphorylation in LOX tumors from mouse xenograft studies.
RAF INHIBITOR COMPOUNDS AND METHODS
-
Page/Page column 82, (2008/06/13)
Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.